June 28, 2024 06:34 PM Eastern Daylight Time
Les nouvelles données portant sur AJOVY® (fremanezumab) dans la prévention de la migraine remettent en question les pauses thérapeutiques
View Full Size
Download
Full Size
JPEG, 2161x776, 220.6 KB
Small
JPEG, 480x172, 53.0 KB
Preview
JPEG, 144x52, 26.9 KB
Thumbnail
JPEG, 120x43, 24.6 KB
Smart Multimedia Gallery
Share
Facebook
Twitter
LinkedIn
Delicious
Reddit
StumbleUpon
Digg
MySpace
Newsvine
Google Bookmark
Yahoo! Bookmark
Email
All News
|
News with Multimedia
>
Press Release: Les nouvelles données portant sur AJOVY® (frema...
Get Business Wire News on Your Website
Terms of Use
|
© 2024 Business Wire